Digest Network Come funziona
Network
/
Società
Pu
Non verificato

PureTech Health plc

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

55 comunicati stampa

Guarda tutti i comunicati
22/04/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
13/04/2026
Mercato azionario
Finanza
Web e Social Network
Telefonia e Varie
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
PureTech Health: Notice of Results
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
02/04/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Sanità
PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
02/04/2026
Industria
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
25/03/2026
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in Humans
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
25/02/2026
Eventi
Web e Social Network
Sanità
Farmaceutica
Salute
PureTech to Present at the Leerink Partners Global Healthcare Conference
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
19/02/2026
Industria
Igiene alimentare
Salute
Scienza
Farmaceutica
Biotecnologia
PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
06/01/2026
Biotecnologia
Farmaceutica
Salute
Eventi
Web e Social Network
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
18/12/2025
PureTech Appoints Robert Lyne as Chief Executive Officer
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
08/12/2025
Multimedialità
Igiene alimentare
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0